Both breast cancer mutants led to an increased tyrosine phosphorylation of FRS2, a well-characterized FGFR2 substrate, as revealed by immunoblotting with anti-p-FRS2 antibody after SDS-PAGE. The gene discussed is FGFR2; the disease is breast carcinoma.